Trial Profile
A Follow-up Evaluation Study of the Safety and Efficacy of PRI-724 Administration in Patients With Cirrhosis Due to Hepatitis C
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2022
Price :
$35
*
At a glance
- Drugs Foscenvivint (Primary)
- Indications Liver cirrhosis
- Focus Adverse reactions
- 17 Jul 2018 Status changed from active, no longer recruiting to completed.
- 17 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Mar 2018.